Review of infliximab or adalimumab treatment
at least every 12 months
tests per year, UK, at least every 12 months
“The need to continue treatment should be reviewed at least every 12 months.”
NICE NG129, Crohn's disease: management, section 1.2, 2019-05
- Kind of source
- Clinical guideline
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- The sentence applies to infliximab in children aged 6 to 17 with severe active Crohn's disease.
Used in
Kept as evidence; no figure on the platform is computed from it yet.